Physician profile
Michael Patrick Mcgonigal
NPI 1013968577
$64,810.75
in general payments reported to CMS, 2019-2025
67 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $17K · 2021: $9,253 · 2022: $4,124 · 2023: $3,146 · 2024: $3,311 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,088 · Education: $20.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,088.41 |
| Education | $20.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45,560.92 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $4,171.18 | 2019-2025 | |
| Amgen INC. | $2,246.61 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,878.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,232.01 | 2019-2025 | |
| Amarin Pharma, INC. | $832.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $816.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $795.71 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $700.32 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $613.75 | 2020-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.06 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $506.30 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Allergan, INC. | $417.67 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $373.48 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $328.84 | 2019-2024 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $268.69 | 2019-2025 | Eliquis |
| Inari Medical, INC. | $214.63 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.01 | 2019-2024 | Xifaxan, Trulance |
| Antares Pharma, INC. | $181.80 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $171.35 | 2021-2025 | Dexcom G6 Transmitter |
| Pulmonx Corporation | $165.26 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.67 | 2025 | Caplyta |
| Astellas Pharma US INC | $144.81 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $138.54 | 2023-2025 | Rexulti |
| Daiichi Sankyo INC. | $137.04 | 2019-2023 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $132.62 | 2019-2022 | |
| Organon LLC | $127.05 | 2021-2025 | Nexplanon |
| Exact Sciences Corporation | $113.11 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $110.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.45 | 2022 | |
| Avanir Pharmaceuticals, INC. | $84.46 | 2019-2021 | |
| Radius Health, INC. | $83.77 | 2019-2020 | |
| Abiomed | $81.11 | 2023-2025 | Impella |
| Nestle Healthcare Nutrition INC. | $80.52 | 2022-2023 | |
| Ardelyx, INC. | $77.13 | 2024-2025 | Ibsrela |
| Eisai INC. | $75.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.87 | 2019-2021 | |
| Genentech USA, INC. | $49.62 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $46.27 | 2019 | |
| Medtronic, INC. | $45.56 | 2021-2024 | Inpen Smart Insulin Delivery System |
| Seqirus USA INC | $41.87 | 2019-2025 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $41.40 | 2021 | |
| Aimmune Therapeutics, INC. | $38.65 | 2024 | |
| Sanofi-Aventis U.S. LLC | $38.58 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $37.92 | 2021 | |
| Corium, LLC | $37.42 | 2022 | |
| Phathom Pharmaceuticals, INC. | $33.88 | 2024 | Voquezna |
| Gilead Sciences, INC. | $32.48 | 2021-2022 | |
| Lundbeck LLC | $29.06 | 2025 | Vyepti |
| Ultragenyx Pharmaceutical INC. | $28.87 | 2020-2021 | |
| Bioventus LLC | $27.50 | 2024 | Durolane |
| Averitas Pharma INC. | $25.42 | 2025 | Qutenza |
| Verona Pharma, INC. | $25.02 | 2025 | Ohtuvayre |
| Supernus Pharmaceuticals, INC. | $24.23 | 2019-2022 | |
| Biogen, INC. | $23.85 | 2021 | |
| Medtronic Minimed, INC. | $23.64 | 2019-2020 | |
| Viiv Healthcare Company | $23.01 | 2022 | |
| Axsome Therapeutics, INC. | $21.33 | 2024 | Auvelity |
| Si-Bone, INC. | $20.22 | 2022 | |
| Edwards Lifesciences Corporation | $19.48 | 2023 | |
| Upsher-Smith Laboratories LLC | $19.26 | 2020 | |
| Shield Therapeutics INC | $18.27 | 2024 | |
| Horizon Therapeutics Plc | $17.50 | 2022 | |
| Indivior INC. | $16.82 | 2024 | Sublocade |
| Azurity Pharmaceuticals, INC. | $15.35 | 2025 | Azmiro |
| Noven Therapeutics, LLC | $14.43 | 2024 | Secuado, Xelstrym |
| Ironwood Pharmaceuticals, INC | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcgonigal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.